| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3039542 | Clinical Neurology and Neurosurgery | 2016 | 5 Pages |
•Preoperative performance status and age still remain the most important predictors to a longer survival.•The median overall survival from diagnosis of glioblastoma resulted 18.5 months.•Extent of resection at reoperation improves overall survival, even in patients with subtotal resection at initial operation.
Optimal treatment for recurrent glioblastoma continues to evolve. Currently, however, there is no consensus in the literature on the role of reoperation in the management of these patients, as several studies provide evidence for a longer overall survival in selected patients with recurrent glioblastoma who underwent second surgery and other studies report a limited impact of second surgery in the clinical course. In this paper, a review of the current literature was performed to analyze the role of reoperation in patients with recurrent glioblastoma and to report the overall survival from diagnosis, progression-free survival and quality of life. Using PubMed and Ovid Medline databases, we performed a review of the literature of the last seven years, finding a total of 28 studies and 2279 patients who underwent second surgery, that were included in the final analysis. The median overall survival from diagnosis and the median survival from second surgery were 18.5 months and 9.7 months, respectively. Extent of resection at reoperation improves overall survival, even in patients with subtotal resection at initial operation. Preoperative performance status and age are important predictors of a longer survival, reason why younger patients with a good preoperative performance status could benefit from reoperation.
